AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for Astellas Pharma US, Inc.�
1.42
-0.12 (-7.79%)
After Hours: 1.40 -0.02 (-1.41%)
Mar 5, 7:33PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.36 - 1.77
52 week 0.61 - 1.96
Open 1.73
Vol / Avg. 0.00/452,695.00
Mkt cap 82.40M
P/E     -
Div/yield     -
EPS -1.08
Shares 66.57M
Beta 1.09
Inst. own 24%
Mar 6, 2015
AVEO Oncology Biomarker Analysis from Phase 2 Clinical Study of Tivozanib in Patients with Advanced Colorectal Cancer - 8:00AM EST - Add to calendar
Jan 15, 2015
Aveo Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1653.61% -8277.57%
Operating margin -1615.01% -8035.89%
EBITD margin - -7121.96%
Return on average assets -60.80% -60.50%
Return on average equity -142.57% -113.33%
Employees 71 -
CDP Score - -

Address

650 E. KENDALL STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2995000 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. The Company�s Human Response Platform (HRP) provides insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. This platform was designed to overcome many of the limitations of traditional approaches to modeling human cancer. The Company�s product candidates include AV-203, Ficlatuzumab, Tivozanib and AV-380. AV-203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin-1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF), inhibitory antibody. AV-380 is for treatment of cachexia. Tivozanib is a potent, selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).

Officers and directors

Tuan Ha-Ngoc Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Michael P. Bailey President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel
Age: 42
Bio & Compensation  - Reuters
Henri A. Termeer Lead Out Side Director
Age: 69
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 64
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Raju S. Kucherlapati Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Robert C. Young M.D Independent Director
Age: 74
Bio & Compensation  - Reuters